6 results on '"Hamouda T"'
Search Results
2. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens
- Author
-
Stanberry, L.R., Simon, J.K., Johnson, C., Robinson, P.L., Morry, J., Flack, M.R., Gracon, S., Myc, A., Hamouda, T., and Baker, J.R.
- Subjects
- *
IMMUNE response , *IMMUNOLOGICAL adjuvants , *SEASONAL influenza , *ANTIGENS , *INTRANASAL medication , *PATHOGENIC microorganisms , *IMMUNOGLOBULIN A , *HEMAGGLUTININ - Abstract
Abstract: Background: Improving the systemic and mucosal immune response following intranasal vaccination could enhance disease protection against respiratory pathogens. We assessed the safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Methods: This was a first-in-human Phase I study in 199 healthy adult volunteers randomized to receive a single intranasal administration of 5%, 10%, 15% or 20% W805EC, combined with 4 or 10μg strain-specific Fluzone® HA, compared with intranasal PBS, intranasal Fluzone®, or 15 ug strain-specific intramuscular Fluzone®. Safety was evaluated by physical examination, laboratory parameters, symptom diaries, and adverse event reports. Serum HAI titers and nasal wash IgA were assessed at baseline as well as 28 and 60days after vaccination. Results: W805EC adjuvant combined with seasonal influenza antigens was well tolerated without safety concerns or significant adverse events. The highest dose of 20% W805EC combined with 10μg strain-specific HA elicited clinically meaningful systemic immunity based on increases in serum HAI GMT and ≥70% seroprotection for all 3 influenza strains, as well as a rise in antigen-specific IgA in nasal wash specimens. Conclusions: W805EC adjuvant was safe and well tolerated in healthy adult volunteers and elicited both systemic and mucosal immunity following a single intranasal vaccination. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
3. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
- Author
-
Bernstein DI, Cardin RD, Bravo FJ, Hamouda T, Pullum DA, Cohen G, Bitko V, and Fattom A
- Subjects
- Adjuvants, Immunologic administration & dosage, Administration, Intranasal, Animals, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Disease Models, Animal, Emulsions administration & dosage, Emulsions chemistry, Female, Guinea Pigs, Herpes Genitalis immunology, Herpesvirus 2, Human, Nanoparticles administration & dosage, Nanoparticles chemistry, Vaccines, Subunit administration & dosage, Vaccines, Subunit therapeutic use, Virus Shedding, Antibodies, Viral blood, Herpes Genitalis prevention & control, Herpes Genitalis therapy, Herpes Simplex Virus Vaccines administration & dosage, Herpes Simplex Virus Vaccines therapeutic use
- Abstract
Genital herpes is a sexually transmitted disease representing a major global health concern. Currently, there is no approved vaccine and existing antiviral therapies exhibit limited efficacy. Herein, we describe an intranasal (IN) vaccine comprised of HSV-2 surface glycoproteins gD2 and gB2 formulated in a nanoemulsion adjuvant (NE01-gD2/gB2). Using the HSV-2 genital herpes guinea pig model, we demonstrate that IN NE01-gD2/gB2 induces higher levels of neutralizing antibody compared to a monovalent IN NE01-gD2 vaccine, but less than an intramuscular (IM) Alum/MPL-gD2 vaccine. Following intravaginal (IVag) challenge with HSV-2, the group immunized with IN NE01-gD2/gB2 exhibited significantly reduced acute and recurrent disease scores compared to placebo recipients. Significantly, latent virus was only detected in the dorsal root ganglia of 1 of 12 IN NE01-gD2/gB2-vaccinated animals compared to 11 of 12 placebo recipient. In the therapeutic model, IN NE01-gD2/gB2 immunized guinea pigs exhibited a significant reduction in the recurrent lesions scores (64%, p < 0.01), number of animal days with disease (64%, p < 0.01), number of animals with viral shedding (50%, p < 0.04) and reduction in virus positive vaginal swabs (56%, p < 0.04), These data suggests that the treatment may be effective in treating chronic disease and minimizing virus transmission. These results warrant advancing the development of IN NE01-gD2/gB2 as both a prophylactic and therapeutic vaccine against HSV-2., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
4. A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.
- Author
-
Ahmed M, Smith DM, Hamouda T, Rangel-Moreno J, Fattom A, and Khader SA
- Subjects
- Adjuvants, Immunologic, Animals, Antigens, Bacterial immunology, Mice, Mice, Inbred C57BL, Tuberculosis immunology, Tuberculosis prevention & control, Interleukin-17 metabolism, Mycobacterium tuberculosis immunology, Mycobacterium tuberculosis pathogenicity, Tuberculosis Vaccines immunology, Tuberculosis Vaccines therapeutic use
- Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) is contracted via aerosol infection, typically affecting the lungs. Mycobacterium bovis bacillus Calmette-Guerin (BCG) is the only licensed vaccine and has variable efficacy in protecting against pulmonary TB. Additionally, chemotherapy is associated with low compliance contributing to development of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb. Thus, there is an urgent need for the design of more effective vaccines against TB. Experimental vaccines delivered through the mucosal route induce robust T helper type 17 (Th17)/ Interleukin (IL) -17 responses and provide superior protection against Mtb infection. Thus, the development of safe mucosal adjuvants for human use is critical. In this study, we demonstrate that nanoemulsion (NE)-based adjuvants when delivered intranasally along with Mtb specific immunodominant antigens (NE-TB vaccine) induce potent mucosal IL-17T-cell responses. Additionally, the NE-TB vaccine confers significant protection against Mtb infection, and when delivered along with BCG, is associated with decreased disease severity. These findings strongly support the development of a NE-TB vaccine as a novel, safe and effective, first-of-kind IL-17 inducing mucosal vaccine for potential use in humans., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
5. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.
- Author
-
Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, and Kawaoka Y
- Subjects
- Administration, Intranasal, Animals, Antibodies, Viral blood, Bronchoalveolar Lavage Fluid immunology, Bronchoalveolar Lavage Fluid virology, Disease Models, Animal, Female, Hemagglutination Inhibition Tests, Immunoglobulin A blood, Immunoglobulin G blood, Mice, Nasal Mucosa immunology, Nasal Mucosa virology, Orthomyxoviridae Infections prevention & control, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated immunology, Adjuvants, Immunologic administration & dosage, Emulsions administration & dosage, Influenza A Virus, H1N1 Subtype immunology, Influenza Vaccines administration & dosage, Influenza Vaccines immunology, Nanostructures administration & dosage
- Abstract
Currently available influenza vaccines provide suboptimal protection. In order to improve the quality of protective immune responses elicited following vaccination, we developed an oil-in-water nanoemulsion (NE)-based adjuvant for an intranasally-delivered inactivated influenza vaccine. Using a prime-boost vaccination regimen, we show that intranasal vaccines containing the W(80)5EC NE elicited higher titers of serum hemagglutination inhibiting (HAI) antibody and influenza-specific IgG and IgA titers compared to vaccines that did not contain the NE. Similarly, vaccines containing the W(80)5EC NE resulted in higher influenza-specific IgA levels in the bronchoalveolar lavage (BAL) fluid and nasal wash when compared to vaccines formulated without NE. The higher antibody titers in mice immunized with the NE-containing vaccines correlated with reduced viral loads in the lungs and nasal turbinates following a high dose viral challenge. Mice immunized with vaccines containing the W(80)5EC NE also showed a reduction in body weight loss following challenge compared to mice immunized with equivalent vaccines produced without NE. Taken together, our results show that the W(80)5EC NE substantially improves the magnitude of protective influenza-specific antibody responses and is a promising mucosal adjuvant for influenza vaccines and vaccines against other mucosal pathogens., (Published by Elsevier Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
6. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.
- Author
-
Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, Sturm TR, Grabinski MS, Landers JJ, Young KS, Chang J, Hamouda T, Olszewski MA, and Baker JR Jr
- Subjects
- Administration, Intranasal, Animals, Antibody Specificity, Bronchoalveolar Lavage Fluid chemistry, Bronchoalveolar Lavage Fluid virology, Cell Division physiology, Cytokines biosynthesis, Emulsions, Female, Flow Cytometry, Immunity, Mucosal drug effects, Immunity, Mucosal immunology, Immunization, Immunoglobulin A biosynthesis, Immunoglobulin G biosynthesis, Influenza Vaccines toxicity, Mice, Mice, Inbred C3H, Pneumonia immunology, RNA, Viral analysis, RNA, Viral biosynthesis, Reverse Transcriptase Polymerase Chain Reaction, Spleen cytology, Spleen immunology, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated immunology, Viral Plaque Assay, Adjuvants, Immunologic pharmacology, Influenza A virus immunology, Influenza Vaccines administration & dosage, Influenza Vaccines immunology, Pneumonia prevention & control
- Abstract
Nanoemulsion, a water-in-oil formulation stabilized by small amounts of surfactant, is non-toxic to mucous membranes and produces biocidal activity against enveloped viruses. We evaluated nanoemulsion as an adjuvant for mucosal influenza vaccines. Mice (C3H/HeNHsd strain) were vaccinated intranasally with 5 x 10(5) plaque forming units (pfu) of influenza A virus (Ann Arbor/6/60 strain) and a nanoemulsion mixture. The mice were challenged on day 21 after immunization with an intranasal lethal dose of 2 x 10(5) pfu of virus. Animals vaccinated with the influenza A/nanoemulsion mixture were completely protected against infection, while animals vaccinated with either formaldehyde-killed virus or nanoemulsion alone developed viral pneumonitis and died by day 6 after the challenge. Mice vaccinated with virus/nanoemulsion mixture had rapid cytokine responses followed by high levels of specific anti-influenza immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies. Specificity of the immune response was confirmed by assessment of the proliferation and cytokine production in splenocytes. This paper demonstrates that nanoemulsion can be employed as a non-toxic mucosal adjuvant for influenza virus vaccine.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.